Letrozole, an aromatase inhibitor, is being researched in preclinical models as a potential treatment for high-grade gliomas, because this cancer frequently expresses estrogen synthase aromatase (CYP19A1). The gene discussed is CYP19A1; the disease is central nervous system cancer.